摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-氯-苯基)-1-甲基-吡咯烷 | 104936-82-5

中文名称
2-(4-氯-苯基)-1-甲基-吡咯烷
中文别名
——
英文名称
2-(4-chloro-phenyl)-1-methyl-pyrrolidine
英文别名
2-(4-Chlor-phenyl)-1-methyl-pyrrolidin;2-<4-Chlor-phenyl>-1-methyl-pyrrolidin;1-Methyl-2-<4-chlorphenyl>-pyrrolidin;Pyrrolidine, 2-(4-chlorophenyl)-1-methyl-;2-(4-chlorophenyl)-1-methylpyrrolidine
2-(4-氯-苯基)-1-甲基-吡咯烷化学式
CAS
104936-82-5
化学式
C11H14ClN
mdl
——
分子量
195.692
InChiKey
IPUNESKKHWBPCW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    118 °C(Press: 9 Torr)
  • 密度:
    1.112±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    3.2
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'ÉTATS LIÉS AU STRESS
    申请人:OTSUKA PHARMA CO LTD
    公开号:WO2010137738A1
    公开(公告)日:2010-12-02
    The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.
    本发明提供了一种新颖的杂环化合物。一种由通式(1)表示的杂环化合物,其中,R1和R2分别独立表示氢;苯基较低烷基基团,可能在苯环和/或较低烷基基团上具有从较低烷基基团等组成的取代基;或环C3-C8烷基较低烷基基团;或类似物;R3表示较低炔基基团或类似物;R4表示可能具有从1,3,4-噁二唑基团(例如,卤素)或从吡啶基团等组成的取代基的苯基团;所述杂环基可能具有至少一个从较低烷氧基等选择的取代基或其盐。
  • Iridium-Catalyzed Asymmetric Hydrogenation of Cyclic Enamines
    作者:Guo-Hua Hou、Jian-Hua Xie、Pu-Cha Yan、Qi-Lin Zhou
    DOI:10.1021/ja808358r
    日期:2009.2.4
    The first highly enantioselective iridium-catalyzed hydrogenation of cyclic enamines has been developed. This new reaction provided an efficient method for the synthesis of optically active cyclic tertiary amines including natural product crispine A.
    已经开发出第一个高度对映选择性的铱催化的环状烯胺氢化。这一新反应为合成包括天然产物crispine A在内的光学活性环状叔胺提供了一种有效的方法。
  • [EN] BICYCLIC IMIDAZOLO DERIVATIVE<br/>[FR] DÉRIVÉ IMIDAZOLO BICYCLIQUE
    申请人:SUMITOMO DAINIPPON PHARMA CO LTD
    公开号:WO2016147659A1
    公开(公告)日:2016-09-22
    Disclosed are compounds, having the following structure, useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions comprising the compounds, and methods of using the same.
    揭示了具有以下结构的化合物,可用作磷酸二酯酶1(PDE1)的抑制剂,包含这些化合物的组合物,以及使用它们的方法。
  • HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS
    申请人:Takahashi Akira
    公开号:US20120065189A1
    公开(公告)日:2012-03-15
    The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R 1 and R 2 , each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R 3 represents a lower alkynyl group or the like; R 4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.
    本发明提供了一种新型杂环化合物。所述杂环化合物的通式(1)表示,其中,R1和R2各自独立地表示氢;苯基低烷基,其可以在苯环上和/或低烷基上具有选自低烷基等的取代基;或环状C3-C8烷基低烷基;或类似物;R3表示低炔基或类似物;R4表示苯基,其可以具有选自1,3,4-噁二唑基(例如,卤素)或选自吡啶基等杂环基的取代基;所述杂环基可以具有至少一个选自低烷氧基等的取代基或其盐。
  • AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF
    申请人:Sugasawa Keizo
    公开号:US20100249088A1
    公开(公告)日:2010-09-30
    [Object] To provide a therapeutic and/or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action. [Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent trkA receptor inhibitory activity, and found to be capable of being used as a therapeutic and/or prophylactic agent which is excellent in efficacy and safety for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, thereby completing the present invention.
    [目的] 提供一种治疗和/或预防下尿道疾病引起的尿频、尿急和尿失禁的治疗剂和/或预防剂,包括膀胱过度活动、伴有下尿道疼痛的各种下尿道疾病,如间质性膀胱炎、慢性前列腺炎等,以及伴有疼痛的各种疾病,基于出色的trkA受体抑制作用。 [解决方案] 发现一种新型的唑类羧酰胺化合物,其中一种噻唑环或噁唑环通过羧酰胺键与苯环、吡啶环、吡嗪环、噻吩环、吡唑环或吡咯环结合,或其盐具有强效的trkA受体抑制活性,并发现它能够被用作治疗和/或预防剂,对于包括膀胱过度活动、伴有下尿道疼痛的各种下尿道疾病,如间质性膀胱炎、慢性前列腺炎等,以及伴有疼痛的各种疾病,具有出色的疗效和安全性,从而完成了本发明。
查看更多

同类化合物

(2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁 阿维巴坦中间体1 阿曲生坦中间体 阿曲生坦 间甲氧基苯乙腈 铂(2+)羟基乙酸酯-吡咯烷-3-胺(1:1:1) 钾2-氧代吡咯烷-1-磺酸酯 钠1-[(9E)-9-十八碳烯酰基氧基]-2,5-二氧代-3-吡咯烷磺酸酯 金刚烷-1-基(吡咯烷-1-基)甲酮 酸-1-吡咯烷-1,4-氨基-2-甲基-1,1,1-二甲基乙基酯,(2S,4R)- 酚丙氢吡咯 试剂3-Mercaptopropanyl-N-hydroxysuccinimideester 西他利酮 血红素酸 螺虫乙酯残留代谢物Mono-Hydroxy 萘吡坦